Vertex Pharmaceuticals forecast annual revenue largely above Wall Street estimates on Monday, banking on robust sales of its ...

Vertex reported solid fourth-quarter numbers throughout its business. While the company's earnings per share came in slightly ...

The biotech is evaluating several cystic fibrosis medicines that could either work alongside Vertex’s top-selling Trikafta or ...

Vertex Pharmaceuticals Inc. will soon lose a member of its leadership team that helped the company achieve major revenue ...

Vertex Pharmaceuticals dominates the market for cystic fibrosis drugs, but Sionna Therapeutics contends the pharma company’s products still have efficacy and safety limitations. Sionna has ...

Stuart Arbuckle, who’s been with Vertex since 2012, plans to retire from his role in July. His departure comes as Vertex ...

Vertex Pharmaceuticals (VRTX) reports Q4 earnings today. Investors are eager for updates on new drug launches and growth ...

Vertex Pharmaceuticals is working toward making its recently approved non-opioid pain medicine Journavx not only broadly ...

Truist Securities increased the price target for Vertex Pharmaceuticals (NASDAQ:VRTX) Incorporated (NASDAQ: VRTX), a $121 ...

To illustrate that point, let's discuss two stocks in the biotech industry that have moved in opposite directions so far this ...

Despite "another impressive quarterly revenue beat" on Tuesday and solid guidance, Vertex stock dipped on light profit.

Drugmakers — major beneficiaries of NIH-backed university research — have been largely silence on the Trump administration's cuts to agency research payments.